# HighLife Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/highlife-medical

- Industry: Medical Devices & Equipment
- Headquarters: Paris, France
- Website: www.highlifemedical.com/
- Total disclosed funding: $40M
- Latest round: Series B (Feb 25, 2021)
- Investors on record: 6

## About

HighLife SAS is dedicated to advancing medical solutions, particularly focusing on treatments for mitral regurgitation using their pioneering HighLife TSMVR device. Founded in 2010 and headquartered in Paris, France, HighLife SAS specializes in the development of medical devices. The company has undergone strategic pivots to focus on its flagship HighLife TSMVR (Trans-septal Mitral Valve Replacement) solution for treating mitral regurgitation. The firm was founded by Georg Börtlein, Malek Nasr, Prof. Rüdiger Lange and Dr. Nicolo Piazza. In September 2026, HighLife Medical raised EUR 80 million in venture funding co-led by Andera Partners, Merieux Equity Partners, Supernova Invest, and Sofinnova Partners, with participation from  US Venture Partners, Sectoral Asset Management, Vi Partners, BNP Paribas Developpement, Capricorn Partners, Critical Path Ventures, European Investment Bank, Pro Benefis Familiae, and Sprim Ventures.

HighLife Medical specializes in medical solutions, particularly focusing on the treatment of mitral regurgitation (MR) through its flagship product, the HighLife TSMVR (Trans-septal Mitral Valve Replacement) solution. This investigational device is designed to address the needs of patients suffering from moderate to severe MR, the most prevalent valvular heart condition globally. The TSMVR solution offers a transcatheter approach that aims to provide alternatives to traditional surgical methods. HighLife Medical primarily targets healthcare providers, including cardiologists and hospitals, across key geographical markets such as the United States and Europe, where the demand for innovative cardiovascular solutions is growing. Revenue generation is facilitated through business-to-business (B2B) transactions with healthcare institutions and specialized medical providers, focusing on the adoption of their advanced cardiac technologies. The revenue structure is based on the delivery of a medical device that addresses critical patient needs, aligning with healthcare providers' goals to improve treatment outcomes in patients with mitral regurgitation. HighLife SAS aims to expand its product line by developing new versions of the TSMVR device, with anticipated launches in upcoming years contingent on regulatory approvals. The company is also exploring expansion into new markets, including additional European countries and the Asia-Pacific region by 2024. The company plans to utilize the September 2026 funding for transcatheter mitral valve replacement system clinical development and commercial expansion.

## Funding rounds

- Series B, Feb 25, 2021, $3M — Vi Partners
- Series B, Apr 4, 2019, $22M — Sofinnova Partners, US Venture Partners, Andera Partners, Sectoral Asset Management
- Series A, Feb 1, 2018, $14M — Sofinnova Partners, LivaNova PLC

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- LivaNova PLC — Series A
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series B